

What is claimed is:

1. An antibody- toxic moiety conjugate comprising: an antibody that
5 specifically recognizes a molecule expressed only on activated T cells and a toxic moiety.

2. The antibody- toxic moiety conjugate of claim 1, wherein the antibody is specifically reactive with CTLA4.

3. The antibody- toxic moiety conjugate of claim 2, wherein the antibody is specifically reactive with human CTLA4.

4. The antibody- toxic moiety conjugate of claim 2, wherein the antibody is a monoclonal antibody.

5. The antibody- toxic moiety conjugate of claim 2, wherein the antibody binds to a region of the CTLA4 molecule that blocks the binding of CTLA4 to CD80 or CD86.

6. The antibody- toxic moiety conjugate of claim 2, wherein the antibody binds to a region of the CTLA4 in spatial proximity to the site of CTLA4 binding to a costimulatory molecule.

7. The antibody- toxic moiety conjugate of claim 2, wherein the substitution of amino acid 83 in the amino acid sequence of human CTLA4 shown in SEQ ID NO:2 results in modulation of binding of the antibody.

8. The antibody- toxic moiety conjugate of claim 2, wherein the toxic moiety is a carbohydrate.

9. The antibody- toxic moiety conjugate of claim 8, wherein the carbohydrate is calicheamicin.

10. The antibody- toxic moiety conjugate of claim 2, wherein the toxic moiety is a naturally occurring bacterial product.

11. The antibody- toxic moiety conjugate of claim 10, wherein the toxic moiety is selected from the group consisting of ricin A chain and saporin.

12. The antibody- toxic moiety conjugate of claim 2, wherein the antibody is produced by a hybridoma selected from the group consisting of: ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), and ATCC Accession No.____ (hybridoma).

13. The antibody- toxic moiety conjugate of claim 2, wherein the antibody is humanized.

✓ ~~14.~~ A humanized antibody that is specifically reactive with human CLTA4, wherein the antibody comprises an amino acid sequence shown in SEQ ID NO:8.

✓ ~~15.~~ A humanized antibody that is specifically reactive with human CLTA4, wherein the antibody comprises an amino acid sequence shown in SEQ ID NO:10.

✓ ~~16.~~ A method of modulating the immune response comprising contacting a cell with an antibody- toxic moiety conjugate of claim 2.

30 17. The method of claim 16, wherein the antibody- toxic moiety conjugate is administered to a subject and the step of contacting is performed *in vivo*.

18. The method of claim 17, wherein the subject is suffering from a disorder or condition that would benefit from downmodulation of an ongoing immune response wherein the disorder or condition is selected from the group consisting of: an autoimmune disorder, an immune response to a graft, an allergic response, an immune response to a therapeutic protein.

19. The method of claim 16, wherein the step of contacting is performed *in vitro*.

20. A method of modulating the immune response comprising contacting a cell with an antibody specifically reactive with CTLA4, wherein the antibody is produced by a hybridoma selected from the group consisting of: ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), ATCC Accession No.____ (hybridoma), and ATCC Accession No.____ (hybridoma).

21. A method of modulating the immune response comprising contacting a cell with an antibody specifically reactive with human CLTA4, wherein the antibody comprises an amino acid sequence shown in SEQ ID NO:8.

22. A method of modulating the immune response comprising contacting a cell with an antibody specifically reactive with human CLTA4, wherein the antibody comprises an amino acid sequence shown in SEQ ID NO:10.

23. A method of downmodulating the immune response comprising contacting a cell with an antibody- toxic moiety conjugate, wherein the antibody specifically recognizes CTLA4.